Moderna (MRNA) Stock Dips While Market Gains: Key Facts

Impact · against what's priced in

The article provides no new catalysts for MRNA; the projected earnings losses and revenue declines are already reflected in the market's valuation and the consensus estimates. The stock's current premium remains tied to the oncology platform and cash burn, neither of which are updated by these static financial projections.

MRNA+0.00

Already priced in

The price assumes

The current respiratory vaccine franchise, which generated $1.94 billion in FY2025 revenue despite a 39.2% year-over-year decline.

The projected quarterly revenue of $888.78 million (down 12.52%) and full-year revenue of $2.11 billion align with the existing pricing of a declining respiratory franchise.

What MRNA's price assumes · Sep 11

• MRNA▲267%
• earnings
• fundamental analysis
• healthcare
• biotechnology
• revenue forecast

Top 1 mover · tap to explore